Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28365095 | 0.91 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL17727833 | 0.85 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL5832212 | 0.85 | TSHR (0.49) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL345837 | 0.84 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL1011657 | 0.83 | TSHR (0.50) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL7909992 | 0.82 | TSHR (0.46) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL28293056 | 0.82 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL9442335 | 0.82 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL1155455 | 0.82 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL28709934 | 0.81 | TSHR (0.49) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1772138-B1 | Organopolysiloxane combination for powder surface treatment | SHINETSU CHEMICAL CO (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7862895-B2 | Organopolysiloxane combination for surface treatment, powder treated with the combination, and cosmetic comprising the powder | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-01-04 | — | — | US | disclosed |
| EP-1618926-B1 | HAIR TREATMENT COMPRISING ACRYLIC/SILICONE COPOLYMER AND COSMETIC HAIR PREPARATION CONTAINING THE TREATMENT | SHINETSU CHEMICAL CO (JP) | 2009-06-03 | — | — | EP | disclosed |
| EP-1772138-A2 | Organopolysiloxane combination for powder surface treatment | Shin-Etsu Chemical Company, Ltd. (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-20070071980-A1 | Organopolysiloxane combination for surface treatment, powder treated with the combination and cosmetic comprising the power | SHIN-ETSU CHEMICAL CO., LTD. | 2007-03-29 | — | — | US | disclosed |
| US-20060198804-A1 | Hair treatment comprising acrylic/silicone copolymer and cosmetic hair preparation containing the treatment | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1618926-A1 | HAIR TREATMENT COMPRISING ACRYLIC/SILICONE COPOLYMER AND COSMETIC HAIR PREPARATION CONTAINING THE TREATMENT | Shin-Etsu Chemical Company, Ltd. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198804-A1 | Hair treatment comprising acrylic/silicone copolymer and cosmetic hair preparation containing the treatment | SUCLG1, SGMS1, HDAC10 | TSHR 3219/4885THRB 2695/4885POLB 1017/4885 |
| US-20070071980-A1 | Organopolysiloxane combination for surface treatment, powder treated with the combination and cosmetic comprising the power | XPA, COL2A1, MSR1 | TSHR 928/4885THRB 1283/4885POLB 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.